ARAmal Ramadan

Amal Ramadan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amal Ramadan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Synthetic Insecticide Fipronil Induced Over Gene Expression, DNA and Liver Damage in Female Rats: The Protective Role of Fish Oil

    by Amel A. Refaie, Amal Ramadan, Nevien M. Sabry, Wagdy K. B. Khalil

    Synthetic insecticide fipronil (FPN) is widely spread worldwide for controlling insects in agriculture and public health sectors. Thus, this work aimed to study the molecular mechanisms of FPN induced hepatotoxicity and the protective role of fish oil in female rats. Female rats were allocated in four groups of rats exposed to FPN and/or fish oil and control. Oxidative stress markers i.e., lipid peroxidation (LPO), antioxidant enzymes, and liver function enzymes, butyryl cholinesterase (BuChE), histopathological lesions, DNA damage, expression alteration of apoptosis and inflammatory related genes in liver tissues were assessed. FPN treatment induced significant changes in the levels of LPO, liver function, BuChE, histopathological lesions, over expression of tested genes and elevation in DNA damage. In contrary, treatment of FPN-exposed rats with fish oil improved significantly the negative effects of FPN on liver tissues. The molecular mechanisms of FPN might be due to the formation of reactive oxygen species (ROS) and change in the oxidant/antioxidant statues. The hepatoprotective effect of fish oil might be attributed to the increase in the antioxidant capacity, which prevented the ROS generation induced by FPN in female rats.


  • Expression of MiR-335 and its target metalloproteinase genes: clinical significance in breast cancer

    by Amal Ramadan, Maha Hashim, Naglaa M. Hassan, Menha Swellam

    Background: Early diagnosis of breast cancer decreases mortality rate; therefore, novel diagnostic methods are urgently required. In this study, authors aimed to investigate the role of serum-derived miR-335 in breast cancer, and the expression of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) and evaluating their feasibility and clinical utility as biomarkers for the early detection of breast cancer. Materials and methods: Blood samples were collected from a total of 210 individuals who were enrolled in this study. The participants were divided into newly diagnosed breast cancer patients (n = 115), patients with benign breast lesions (n =55) and healthy individuals as control group (n =40). The expression profile of miR-335, MMP2 and MMP9 were determined using quantitative polymerase chain reaction (qPCR). Results: MiR 335 expression level was down-regulated in primary breast cancer group as compared to benign breast group and healthy individuals with 98% and 94.9% sensitivity and specificity, respectively. MMP2 and MMP9 showed significantly higher expression levels in breast cancer group as compared to both benign and healthy group and reporting 92.7% and 93% sensitivity, respectively. The relations between investigated markers and pathologic types, staging, grading, and lymph node involvement were significant with these factors. Expression level of miR-335 was decreased with increased MMP2 and MMP9 at significant level. Conclusion: MiR-335, MMP2, and MMP9 can be used as diagnostic markers in breast cancer.


  • Clinical significance of blood‐based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers

    by Menha Swellam, Amal Ramadan, Enas A. El‐Hussieny, Noha M. Bakr, Naglaa M. Hassan, Mohamed Emam Sobeih, Lobna R. EzzElArab

    MicroRNAs (miRNAs) are implicated in carcinogenesis and their expression in biological fluids offer great potential as nucleic acid markers for cancer detection and progression. Authors investigated the expression level of miRNAs (miRNA‐21, miRNA‐126, and miRNA‐155) to evaluate their role as diagnostic and prognostic markers for breast cancer compared with other commonly used protein‐based markers (CEA and CA15‐3). Serum samples from patients with breast cancer (n = 96), patients with benign breast lesion (n = 47), and healthy individuals (n = 39) were enrolled for detection of miRNA expression levels and protein‐based tumor markers using fluorescent real‐time quantitative polymerase chain reaction and enzyme‐linked immunosorbent assay, respectively. Correlation among investigated markers with clinicopathological factors and clinical outcomes were determined. Expression of miRNA‐21 and miRNA‐155 revealed significant increases in patients with breast cancer compared with both benign and control groups, the same result was reported for tumor markers; on the other hand, miRNA‐126 was significantly decreased in breast cancer group as compared with the other two groups. miRNA frequencies were significantly related to clinical staging and histological grading as compared with tumor markers. Patients with breast cancer with increased miRNA‐21 and miRNA‐155 and decreased miRNA‐126 expressions had significantly worse disease‐free survival, while only miRNA‐21 and miRNA‐126 showed poor OS (P< 0.005). In conclusion, investigated miRNAs were superior over tumor markers for the early stage of breast cancer especially those with high‐risk factor and their assessment in blood facilitates their role as a potential prognostic molecular marker.


  • Aberrant Expression of Some Circulating miRNAs in Childhood Acute Lymphoblastic Leukemia

    by Menha Swellam, Maha Hashim, Magda Sayed Mahmoud, Amal Ramadan, Naglaa M. Hassan

    Acute lymphoblastic leukemia (ALL) is a heterogeneous cancer commonly affecting children due to dysregulation of miRNA expression. In the current study, authors investigated the expression profile for miRNA-125b-1 and miRNA-203 among childhood ALL. Blood samples were collected from newly diagnosed childhood ALL and healthy control children. The expression profile for candidate miRNAs was detected using quantitative RT-PCR analysis. Statistical analysis were performed using receiver operating characteristic curve (ROC) to examine the diagnostic efficacy of the two miRNA and their levels among ALL clinicopathological factors and phenotypes. The median expression level for miRNA-125b-1 was significantly high in childhood ALL; while miRNA-203 level was significantly low in childhood ALL as compared to control ones. MiRNA-125-1 reported significant increase in T-ALL as compared to other ALL phenotypes. Median miRNA-203 level was high in T-ALL followed by pre-B-ALL although no significant difference was reported. Clinicopathological factors did not emphasize significance with either detected miRNAs. Using ROC curve the diagnostic efficacy was significant with an area under the curve 0.858 for miRNA-125b-1 (83.72, 100%) and 0.878 for miRNA-203 (97.67, 86.96%). The combination of the two key miRNAs revealed absolute sensitivity (100%). MiRNA-125b-1 and miRNA-203 can be useful molecular markers for diagnosis of ALL. Further studies with large cohort are warranted to validate these results.


  • Open Access

    Diagnostic Role of Aberrant DNA Promoter Methylation in Ovarian Cancer

    by Menha Swellam, Amal Ramadan, Magda Sayed Mahmoud, Maha Hashim, Mohamed Emam

    Background: Alteration of DNA methylation of CpG islands in the promoter regions of tumor suppressor genes is associated with cancer development. We aimed to examine the diagnostic efficacy role of promoter methylated tumor suppressor genes: DAPK, OPCML and DLEC1 in ovarian cancer patients. Materials and Methods: One hundred forty patients were enrolled (90 with epithelial ovarian cancer [EOC] while the remaining 50 were suffering from benign ovarian lesions. A group of healthy individuals (n=30) were included as control group. Methylation pattern were detected by methylation specific polymerase chain reaction (MSP) in serum samples from all individuals and protein based markers (CEA and CA125) were also estimated. Results: Promoter methylation was significant for DAPK, OPCML and DLEC1 in EOC as compared to benign ones while all control cases were unmethylated. Significant relation was reported between DAPK, OPCML hypermethylation and FIGO stage, histopathological type and histological grade while DLEC1 hypermethylation was related to both FIGO stage (P= 0.03) and histological grading (PConclusion: Promoter methylation of DAPK, OPCML and DLEC1 genes in circulating blood serves as promising diagnostic approach for early detection of EOC particularly those with early stages, low - grade tumors.


  • Open Access

    Aberrant methylation of APC and RARβ2 genes in breast cancer patients

    by Menha Swellam, Mohamed D.E. Abdelmaksoud, Magda Sayed Mahmoud, Amal Ramadan, Walid Abdel‐Moneem, Mona M. Hefny

    Changes in the status of DNA methylation are one of the most common molecular alterations in human neoplasia. We aimed to identify epigenetic molecular markers in serum for early detection of breast cancer. Authors analyzed retrospectively the methylation status of RARβ2 and APC genes in serum samples from 121 breast cancer patients, 79 patients with benign breast diseases, and 66 healthy volunteers using methylation‐specific PCR. The methylated APC and RARβ2 were significantly higher in breast cancer patients (93.4%, 95.6%) than benign (7.8%, 14.5%) but not detected in healthy volunteers (0%) at (P < 0.0001). Both methylated genes showed no significant difference among clinicopathological factors apart from triple negative breast cancer patients as all of them (χ2 = 7.4, P = 0.007) reported to be methylated RARβ2 genes. Both methylated genes were detected in all grades and stages. Both sensitivities and specificities of the methylated genes for breast cancer detection were superior to traditional tumor markers in detection of breast cancer, early stage, low grade tumors, and triple negative breast cancer patients. Thus methylated APC and RARβ2 genes might be valuable serum‐based molecular markers for early detection of breast cancer. © 2015 IUBMB Life, 67(1):61–68, 2015


  • Open Access

    Oxidative damage and nephrotoxicity induced by prallethrin in rat and the protective effect of Origanum majorana essential oil

    by Amel Abd El-Rahman Refaie, Amal Ramadan, Abdel-Tawab Halim Mossa

    To investigate the effects of prallethrin on renal dysfunction biomarkers, antioxidant enzyme activities and lipid peroxidation (LPO) in rats and the protective effect of Origanum majorana essential oil. Rats were divided into four groups of seven rats in each group: (I) received only olive oil, (II) treated with 64.0 mg/kg body weight prallethrin (1/10 LD50) in olive oil via oral route daily for 28 d, (III) treated with 64.0 mg/kg body weight prallethrin (1/10 LD50) and essential oil (160 μL/kg body weight) in olive oil and (IV) received essential oil (160 μL/kg body weight) in olive oil via oral route twice daily for 28 d. Prallethrin caused significant increase in LPO and decrease in superoxide dismutase, glutathione peroxidase and glutathione reduced. Consistent histological changes were found in the kidney of prallethrin treatment. Co-administration of essential oil attenuated the prallethrin induced renal toxicity and oxidative stress by decreasing LPO in kidney, creatinine, urea and uric acid levels in serum. In addition, superoxide dismutase, glutathione peroxidase activity and glutathione reduced level were increased in kidney in prallethrin-essential oil groups. We can conclude that prallethrin induced oxidative damage and renal toxicity in male rat. The administration of essential oil provided significant protection against prallethrin-induced oxidative stress, biochemical changes and histopathological damage.


  • Open Access

    Amelioration of Prallethrin-Induced Oxidative Stress and Hepatotoxicity in Rat by the Administration ofOriganum majoranaEssential Oil

    by Abdel-Tawab H. Mossa, Amel A. Refaie, Amal Ramadan, Jalloul Bouajila

    This study was carried out to evaluate the adverse effects of exposure to prallethrin on oxidant/antioxidant status and liver dysfunction biomarkers and the protective role ofOriganum majoranaessential oil (EO) in rat. Male rats were divided into 4 groups: (i) received only olive oil (ii) treated with 64.0 mg/kg body weight prallethrin (1/10 LD50) in olive oil via oral route daily for 28 days, (iii) treated with 64.0 mg/kg body weight prallethrin (1/10 LD50) and EO (160 μL/kg b.wt.) in olive oil and (iv) received EO (160 μL/kg b.wt.) in olive oil via oral route twice daily for 28 days. Prallethrin treatment caused decrease in body weight gain and increase in relative liver weight. There was a significant increase in the activity of serum marker enzymes, aspartate transaminase, alanine transaminase, and alkaline phosphatase. It caused increase in thiobarbituric acid reactive substances and reduction in the activities of superoxide dismutase, catalase, and glutathione-S-transferase in liver. Consistent histological changes were found in the liver of prallethrin treatment. EO showed significant protection with the depletion of serum marker enzymes and replenishment of antioxidant status and brought all the values to near normal, indicating the protective effect of EO. We can conclude that prallethrin caused oxidative damage and liver injury in male rat and co-administration of EO attenuated the toxic effect of prallethrin. These results demonstrate that administration of EO may be useful, easy, and economical to protect human against pyrethroids toxic effects.


  • Antimutagenic Effect of Origanum majorana L. Essential Oil Against Prallethrin-Induced Genotoxic Damage in Rat Bone Marrow Cells

    by Abdel-Tawab H. Mossa, Amel A. Refaie, Amal Ramadan, Jalloul Bouajila

    This study aimed to investigate the genotoxic and cytotoxic potential of prallethrin in rat bone marrow cells and the protective effect of Origanum majorana L. essential oil (EO). Our results demonstrated that prallethrin at dose 64.0 mg/kg body weight (b.wt.) (1/10 LD50), has a clastogenic/genotoxic potential as shown by the high percentage of chromosomal aberration (CA) and micronucleus (MN) in the bone marrow cells of male rats, whereas the combined treatment of prallethrin and O. majorana EO resulted in the reduction of the CA (54.54%). The combined treatment also reduced the micronuclei formation significantly. In conclusion, prallethrin can be considered clastogenic/genotoxic and may carry a risk to human health. The study revealed the antigenotoxic and anticytotoxic potential of O. majorana EO against prallethrin-induced genotoxic and cytotoxic effects in rat bone marrow cells.